CytoDyn Inc. cotiza a 0.20 USD y tiene una capitalización bursátil de $294M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
CytoDyn Inc., a clinical-stage biotechnology company, develops treatments for multiple therapeutic indications. The company develops leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19. Its leronlimab completed phase 2 development for the treat…
| Periodo | 2026-10 | 2025-09 | 2021-04 | 2021-01 |
|---|---|---|---|---|
| Real | — | — | $-0.05 | $-0.06 |
| Estimado | — | — | $-0.05 | $-0.05 |
| Sorpresa | — | — | +0.0% | -20.0% |
| Métrica | CYDY | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | — | -40.4% | — |
| ROA | -305.6% | -32.0% | -273.6% |
| Current Ratio | 0.26 | 2.84 | -2.58 |
| Debt / Equity | -0.35 | 0.28 | -0.63 |